Navigation Links
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Date:5/6/2009

isk patients) and maintained this lower level throughout the primary endpoint. The effect was more pronounced for patients achieving LDL-C below 50 mg/dL.

"Building on strong results from our first two clinical studies in stable cardiovascular patients, the FRANCIS study has validated the potential utility of aggressive varespladib treatment to improve outcomes in a high-risk patient population immediately following an ACS event," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "In addition to meeting the primary and several secondary endpoints, clinical data from the FRANCIS study has met and/or exceeded our expectations and we hope to present the entire data set including biomarkers, safety, and secondary clinical endpoints (MACE) at an upcoming scientific conference."

"We are extremely excited by these data," said Colin Hislop, M.D., Senior Vice President Clinical Development at Anthera. "The favorable treatment effect of varespladib is consistent with our Phase 3 development plan and provides a robust data set to support substantial clinical benefit for this novel, first in class therapy."

With approximately 1000 patient exposures to date in three cardiovascular studies, varespladib has been generally well tolerated.

About the FRANCIS trial

The FRANCIS trial is based upon direct feedback from Food and Drug Administration via the Special Protocol Assessment process. FRANCIS was designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. It enrolled 625 patients who will be treated for a minimum of six months. The study is being conducted at sites in Europe. FRANCIS is designed to provide insight into the potential prevention of secondary Major Adverse Cardiovascular Events (MACE) by varespladib. In this study, MACE was defined as a composite endpoint consisting of all-cause mortali
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Corporation (NASDAQ: CYTR ), a biopharmaceutical research and ... for the three months ended June 30, 2015, and ... milestones for its clinical development programs. "The ... CytRx. Enrollment in our ongoing pivotal global Phase 3 ... continues on track to be completed in the first ...
(Date:8/3/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., ... call will cover an update on Merrimack,s progress as ... A press release detailing the information to be discussed ... Monday, August 10. Investors and the general public are ...
(Date:8/3/2015)... Aug. 3, 2015  Celsion Corporation (NASDAQ: ... host a conference call to discuss its second ... on its development programs for ThermoDox®, its proprietary ... acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy ... Monday, August 10, 2015. To participate in the ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... 29, 2011 Robbins & Myers, Inc. ... sale of its Romaco businesses to a group of ... private equity investment firm.  Total consideration was approximately euro ... of cash and euro 4 million of assumed liabilities ...
... SILVER SPRING, Md., April 29, 2011 Don,t let expired ... dispose of them properly to prevent them from harming others. ... part in the second annual National Prescription Drug Take-Back Day, ... View a slideshow and read a Consumer Update ...
Cached Medicine Technology:
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental Trading Company, ... toys, novelties, and school supplies, has developed engaging and affordable teacher supplies based ... includes student rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant ...
(Date:8/4/2015)... ... 2015 , ... It is National Psoriasis Awareness Month, and we are reminded ... as dry, itching, burning or soreness of skin that may crack or bleed. , ... what’s right for them. Then, what is effective may stop working, so they have ...
(Date:8/4/2015)... ... ... The goal of looking younger – with a fresher, more rested appearance ... ideal is not. But minimally invasive procedures such as dermal fillers, tighteners or laser ... time, according to Valerie Goldburt, MD, PhD , of Advanced Dermatology P.C. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Nathan’s Famous was recently featured ... medium, and large businesses making an impact in their industry. Andrew Tropeano, the host ... the famous hot dog maker now offers a 50% Reduced Fat All-Beef Frank ...
Breaking Medicine News(10 mins):Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3
... and ,Samantha Who?, to be Honored at Donate Life Film ... June 5 On June 13, Donate Life Hollywood will ... "Samantha Who?" with its first annual Inspire Award. This honor, ... be presented at the culmination of the daylong Donate Life ...
... evident with seniors, researchers say , FRIDAY, June 5 (HealthDay ... new generation of video games that require users to get ... bit more fit. , New research suggests that several exercise-based ... equal to that of light jogging. , And seniors in ...
... Joseph F. Finn, Jr., C.P.A. ("Finn") announced today ... Cancer Research Ltd., Brussels Branch. The statement is quoted ... product candidate, GCS-100, is a carbohydrate molecule which inhibits the ... a broad range of human cancers. Prospect reported that ...
... show, , FRIDAY, June 5 (HealthDay News) -- One reason ... not that interesting. But what if you could dance your ... suggest that you just might be able to do that. ... meeting in Seattle, one study found that salsa dancing could ...
... region are ready to prescribe and dispense medications electronically , ... of Spain and IBM (NYSE: IBM ) have ... where health centres and pharmacies are now computerised and able ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ...
... are experiencing onerous fatigue four months after the infarction. The ... infarction as a sign of chronic illness, those who experience ... that the illness has a large impact on their life. ... Sahlgrenska Academy, University of Gothenburg, Sweden. Just over 200 ...
Cached Medicine News:Health News:ABC-TV Gets It Right According to Organ Donation Community 2Health News:Interactive Video Games Offer Exercise Benefits 2Health News:Interactive Video Games Offer Exercise Benefits 3Health News:Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule 2Health News:Finding Fitness on the Dance Floor 2Health News:Finding Fitness on the Dance Floor 3Health News:Spain's Regional Extremadura Government Launches Electronic Prescription System With IBM 2Health News:Fatigue common after myocardial infarction 2